Condition: Adenoid Cystic Carcinoma · Sinonasal Carcinoma · Sponsor: Eye & ENT Hospital of Fudan University
This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity/sinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.
This description comes directly from the study's public registry record.
Quan Liu, MD · +86 15001959681 · liuqent@163.com
Wanpeng Li, MD · +86 13262856870 · 18879117831@163.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Third Xiangya Hospital, Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| The First Affiliated Hospital of China Medical University | Shenyang, Liaoning, China | Not Yet Recruiting |
| Eye & ENT Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| The First Affiliated Hospital of Air Force Medical University | Xi’an, Shanxi, China | Not Yet Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07652489